{
    "nctId": "NCT01842321",
    "briefTitle": "Abiraterone Acetate in Molecular Apocrine Breast Cancer",
    "officialTitle": "A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Clinical benefit rate (CBR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged \u226518 years;\n* Histologically confirmed locally advanced or metastatic breast cancer;\n* Triple negative breast cancer:\n\nEstrogen receptor (ER)-negative and Progesterone receptor (PR)-negative, as defined by a \\<10 % tumour stained cells by immunohistochemistry (IHC); HER2 negative status (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), confirmed centrally before inclusion with FFPE tissue from either primary or metastatic breast cancer site\\*;\n\n* Androgen receptor (AR)-positive, as defined centrally by a \u226510% tumour stained cells by IHC (AR assessment by local pathologist before inclusion is not mandatory);\n* Patients could be chemotherapy na\u00efve (provided they are not presenting with life-threatening metastasis) or have received any number of previous lines of chemotherapy (providing their life expectancy is \u22653 months);\n* Pre and post menopausal patients are eligible.\n* Measurable or non measurable disease according to RECIST v1.1 criteria;\n* PS (ECOG) \u22642;\n* Normal haematological function: ANC \u22651,500/mm3; platelets count \u2265100,000/mm3; haemoglobin \\>10 g/dl;\n* Normal hepatic function: total bilirubin \u22641.5 upper normal limit (UNL); ASAT and ALAT \u22642.5 UNL (\u22645 UNL in the presence of liver metastases);\n* Creatinine clearance (MDRD formula) \u226550 mL/min OR creatinine \u22641.5 times ULN;\n* Normal kalemia (serum potassium \u22653.5 mM), natremia and magnesemia;\n* Systolic blood pressure (BP) \\<160 mm Hg and diastolic BP \\<95 mm Hg, as documented on inclusion day (Hypertension at baseline assessment allowed provided it is currently controlled under anti-hypertensive drugs);\n* Cardiac ejection fraction \u226550% measured by MUGA or ECHO done within 4 weeks before inclusion;\n* If receiving a bisphosphonate or denosumab, dose must have been stable for at least 2 doses before inclusion;\n* Patient agreeing to use effective contraception during and for \u2265 6 months after completion of study treatment;\n* Patient able to comply with the protocol;\n* Patient must have signed a written informed consent form prior to any study specific procedures;\n* Patient must be affiliated to a Social Health Insurance.\n\nExclusion Criteria:\n\n* Male breast cancer;\n* HER2-positive status (positivity defined as IHC3+ and/or FISH amplification \\>2.2);\n* Other concurrent malignancies, except adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin; patients who have undergone potentially curative therapy for a prior malignancy are eligible provided there is no evidence of disease for \u2265 5 years and patient is deemed to be at low risk for recurrence;\n* Active brain metastases or leptomeningeal disease; History of brain metastases allowed provided lesions are stable for at least 3 months as documented by head CT scan or MRI of the brain;\n* Non-malignant systemic disease, including active infection or concurrent serious illness that would make the patient a high medical risk;\n* Significant cardiovascular disease, including any of the following:\n\n  1. NYHA class III-IV congestive heart failure;\n  2. Unstable angina pectoris or myocardial infarction within the past 6 months;\n  3. Severe valvular heart disease;\n  4. Ventricular arrhythmia requiring treatment.\n* Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not be included;\n* Patients with known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone, or their excipients;\n* Persistent toxicities \u2265 grade 2 from any cause, except chemotherapy-induced alopecia and Grade 2 peripheral neuropathy;\n* Active or uncontrolled autoimmune disease requiring concurrent corticosteroid therapy;\n* Any gastrointestinal disorder interfering with absorption of the study drug;\n* Difficulties with swallowing study capsules;\n* Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy, chemotherapy (CT) within the last 3 weeks (2 weeks for oral or weekly CT ; 6 weeks for nitrosoureas and mitomycin C), or other investigational agents ; Concurrent palliative radiotherapy allowed;\n* Concurrent enrolment in another clinical trial in which investigational therapies are administered;\n* Pregnant women, women who are likely to become pregnant or are breast-feeding;\n* Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;\n* Patients with history of non compliance to medical regimens or unwilling or unable to comply with the protocol;\n* Individual deprived of liberty or placed under the authority of a tutor.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}